AIM ImmunoTech Inc. (NYSE:AIM) was up 6.5% during mid-day trading on Tuesday . The company traded as high as $0.46 and last traded at $0.49, approximately 89,930 shares changed hands during mid-day trading. A decline of 63% from the average daily volume of 244,692 shares. The stock had previously closed at $0.46.
Separately, Maxim Group raised shares of AIM ImmunoTech from a “hold” rating to a “buy” rating in a report on Thursday, October 10th.
The company has a debt-to-equity ratio of 0.33, a current ratio of 3.01 and a quick ratio of 3.01. The business’s 50 day moving average is $0.50.
AIM ImmunoTech Company Profile (NYSE:AIM)
AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Featured Article: What impact do institutional investors have on markets?
Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.